Sustainable Growth and Rebuilding the Earnings Structure
First written in FY2016. 28 of 36 entries say "Restated". Latest entry: 2026-08-03.
106 other companies' latest entry also says "Restated".
- 2026-08-03RestatedEarnings
「In fiscal 2025, we formulated the 25-27 Medium-Term Management Plan, positioned as the "three years of accelerating the growth strategy," and are pursuing the priority themes of "strengthening the profitability of core businesses," "continued investment in growth businesses," and "strengthening the management foundation supporting growth."」
Reconfirms the positioning of the 25-27 Medium-Term Management Plan and its 3 priority themes. - FY2026RestatedAnnual report
「In fiscal 2025, we formulated the 25-27 Medium-Term Management Plan, positioned as "3 years of accelerating the growth strategy" toward achieving the "desired position in 2031," and are focusing on the following key themes: "strengthening the earnings power of core businesses," "continued investment in growth businesses," and "strengthening the management foundation supporting growth."」
The 3 key themes of the 25-27 Medium-Term Management Plan continue to be presented, with no material changes to the existing direction of growth, investment, and management foundation strengthening. - FY2026-H1RestatedAnnual report
「In fiscal 2025, we formulated the 25-27 Medium-Term Management Plan, positioned as "3 years of accelerating the growth strategy" toward achieving our desired position. Under this plan, we are focusing on the following key themes: "strengthening the earnings power of core businesses," "continued investment in growth businesses," and "strengthening the management foundation supporting growth."」
The 25-27 Medium-Term Management Plan is positioned as "3 years of accelerating the growth strategy," reaffirming the existing long-term vision and the direction of growth, investment, and management foundation strengthening. - FY2025ReframedAnnual report
「The 25-27 Medium-Term Management Plan period is positioned as "3 years of accelerating the growth strategy," and we aim to achieve further growth.」
The 25-27 Medium-Term Management Plan was repositioned from the 22-24 Medium-Term Management Plan's "3 years of building the foundation" as "3 years of accelerating the growth strategy," placing greater emphasis on accelerating growth. - FY2025-H1RestatedAnnual report
「To grow as a distinctive life sciences and healthcare-related corporate group whose value is recognized globally by meeting medical and healthcare needs, the Group (the Company and its consolidated subsidiaries; the same applies below) is bringing together its comprehensive capabilities from research and development through manufacturing and sales, pursuing selective focus for sustainable growth, and pursuing the rebuilding of its earnings structure to respond to further changes in the business environment. During the 22-24 Medium-Term Management Plan period, including the current fiscal year, we are focusing on the following key issues: "maximizing earnings in priority areas centered on new drugs," "investing in business activities that will strengthen future competitiveness," and "strengthening the corporate structure to create innovation and improve productivity."」
Sustainable growth, selective focus, rebuilding the earnings structure, and the 3 key issues continue to be presented during the 22-24 Medium-Term Management Plan period. - FY2024-Q3RestatedAnnual report
「The Group (the Company and its consolidated subsidiaries; the same applies below) is pursuing the rebuilding of its earnings structure by bringing together its comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and responding to further changes in the business environment. To this end, we are focusing on the following key issues: "maximizing earnings in priority areas centered on new drugs," "investing in business activities that will strengthen future competitiveness," and "strengthening the corporate structure to create innovation and improve productivity."」
Sustainable growth, selective focus, rebuilding the earnings structure, and the 3 key issues continue to be presented, with no material changes stated. - FY2024-Q2RestatedAnnual report
「The Group (the Company and its consolidated subsidiaries; the same applies below) is pursuing the rebuilding of its earnings structure by bringing together its comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and responding to further changes in the business environment. To this end, we are focusing on the following key issues: "maximizing earnings in priority areas centered on new drugs," "investing in business activities that will strengthen future competitiveness," and "strengthening the corporate structure to create innovation and improve productivity."」
The basic policy of sustainable growth, selective focus, and rebuilding the earnings structure, together with the 3 key issues, continues to be presented. - FY2024-Q1RestatedAnnual report
「The Group (the Company and its consolidated subsidiaries; the same applies below) is pursuing the rebuilding of its earnings structure by bringing together its comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and responding to further changes in the business environment. To this end, we are focusing on the following key issues: "maximizing earnings in priority areas centered on new drugs," "investing in business activities that will strengthen future competitiveness," and "strengthening the corporate structure to create innovation and improve productivity."」
Sustainable growth, selective focus, rebuilding the earnings structure, and the 3 key issues continue to be presented, with no material changes stated. - FY2023RestatedAnnual report
「The Group is pursuing the rebuilding of its earnings structure by bringing together its comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and responding to further changes in the business environment. To this end, we are focusing on the following key issues: "maximizing earnings in priority areas centered on new drugs," "investing in business activities that will strengthen future competitiveness," and "strengthening the corporate structure to create innovation and improve productivity."」
The 22-24 Medium-Term Management Plan continues to present the basic policy of sustainable growth, selective focus, and rebuilding the earnings structure, together with the 3 key issues. - FY2023-Q3RestatedAnnual report
「The Group (the Company and its consolidated subsidiaries; the same applies below) will bring together its comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursue selective focus for sustainable growth, and rebuild its earnings structure to respond to further changes in the business environment. To this end, we are focusing on the following key issues: "maximizing earnings in priority areas centered on new drugs," "investing in business activities that will strengthen future competitiveness," and "strengthening the corporate structure to create innovation and improve productivity."」
Sustainable growth, selective focus, rebuilding the earnings structure, and the 3 key issues continue to be presented, with no material changes stated. - FY2023-Q2RestatedAnnual report
「The Group (the Company and its consolidated subsidiaries; the same applies below) will bring together its comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursue selective focus for sustainable growth, and rebuild its earnings structure to respond to further changes in the business environment. To this end, we are focusing on the following key issues: "maximizing earnings in priority areas centered on new drugs," "investing in business activities that will strengthen future competitiveness," and "strengthening the corporate structure to create innovation and improve productivity."」
Sustainable growth, selective focus, rebuilding the earnings structure, and the 3 key issues continue to be presented. - FY2023-Q1RestatedAnnual report
「The Group (the Company and its consolidated subsidiaries; the same applies below) will bring together its comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursue selective focus for sustainable growth, and rebuild its earnings structure to respond to further changes in the business environment. To this end, we are focusing on the following key issues: "maximizing earnings in priority areas centered on new drugs," "investing in business activities that will strengthen future competitiveness," and "strengthening the corporate structure to create innovation and improve productivity."」
The Group continues to present sustainable growth, selective focus, and rebuilding the earnings structure in line with the 22-24 Medium-Term Management Plan, and has identified 3 key issues. - FY2022ReframedAnnual report
「The Group has defined its long-term vision as "growing as a distinctive life sciences and healthcare-related corporate group whose value is recognized globally by meeting medical and healthcare needs." To give concrete form to this long-term vision, we formulated the Group's desired position in 2031.」
While carrying forward the previous medium-term management plan policy, the Group has set out its long-term vision and desired position in 2031, and positioned the 22-24 Medium-Term Management Plan as an action plan. - FY2022-Q3RestatedAnnual report
「Against this backdrop, during the third quarter of the current fiscal year, the Group (the Company and its consolidated subsidiaries; the same applies below) focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus," based on the basic policy of prioritizing profits while continuing to invest for the future in order to continue sustainable growth while responding to changes in the business environment.」
The basic policy of prioritizing profits while continuing to invest for the future and the 3 existing key initiatives continued during the third quarter of the current fiscal year. - FY2022-Q2RestatedAnnual report
「Against this backdrop, during the second quarter of the current fiscal year, the Group (the Company and its consolidated subsidiaries; the same applies below) focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus," based on the basic policy of prioritizing profits while continuing to invest for the future in order to continue sustainable growth while responding to changes in the business environment.」
The basic policy of prioritizing profits while continuing to invest for the future and the 3 existing key initiatives continue to be presented. - FY2022-Q1RestatedAnnual report
「Against this backdrop, during the first quarter of the current fiscal year, the Group (the Company and its consolidated subsidiaries; the same applies below) focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus," based on the basic policy of prioritizing profits while continuing to invest for the future in order to continue sustainable growth while responding to changes in the business environment.」
The basic policy of prioritizing profits while continuing to invest for the future and the 3 key initiatives associated with the 21-23 Medium-Term Management Plan continue to be presented. - FY2021ReframedAnnual report
「The policy of the Group's 3-year medium-term management plan (the "21-23 Medium-Term Management Plan") is to "bring together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursue selective focus for sustainable growth, and rebuild our earnings structure to respond to further changes in the business environment," and we will continue to focus on the following 3 areas so that we can respond to changes in the business environment.」
The plan was updated from the 20-22 Medium-Term Management Plan to the 21-23 Medium-Term Management Plan. The basic policy of sustainable growth, selective focus, and rebuilding the earnings structure, together with the 3 key initiatives, has been maintained. - FY2021-Q3RestatedAnnual report
「Against this backdrop, during the third quarter of the current fiscal year, the Group (the Company and its consolidated subsidiaries; the same applies below) focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus," based on the basic policy of prioritizing profits while continuing to invest for the future in order to continue sustainable growth while responding to changes in the business environment.」
The policy of prioritizing profits while continuing to invest for the future, together with the policy of pursuing the 3 key initiatives, continues to be presented. - FY2021-Q2RestatedAnnual report
「Against this backdrop, during the second quarter of the current fiscal year, the Group (the Company and its consolidated subsidiaries; the same applies below) focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus," based on the basic policy of prioritizing profits while continuing to invest for the future in order to continue sustainable growth while responding to changes in the business environment.」
The basic policy of prioritizing profits while continuing to invest for the future, together with the medium-term policy of pursuing the 3 key initiatives, continues to be presented. - FY2021-Q1RestatedAnnual report
「Against this backdrop, during the first quarter of the current fiscal year, the Group (the Company and its consolidated subsidiaries; the same applies below) focused on "concentrating on new drugs and other products," "continued investment to build the next generation of core businesses," and "the strategic reallocation of resources through selective focus," based on the basic policy of prioritizing profits while continuing to invest for the future in order to continue sustainable growth while responding to changes in the business environment.」
The basic policy and 3 key initiatives associated with the 20-22 Medium-Term Management Plan continue to be presented, with no material changes to the policy stated. - FY2020ReframedAnnual report
「The policy of the Group's 3-year medium-term management plan (the "20-22 Medium-Term Management Plan") is to "bring together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursue selective focus for sustainable growth, and rebuild our earnings structure to respond to further changes in the business environment," and we will continue to focus on the following 3 areas so that we can respond to changes in the business environment.」
The plan was updated from the fiscal 2019–2021 plan to the fiscal 2020–2022 "20-22 Medium-Term Management Plan." The basic policy of sustainable growth, selective focus, and rebuilding the earnings structure has been maintained. - FY2020-Q3RestatedAnnual report
「In the medium-term management plan for fiscal 2019 through fiscal 2021 announced on 1 April 2019, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure to respond to further changes in the business environment, we would focus on (1) concentrating on new drugs and other products by strengthening sales capabilities, (2) continued investment to build the next generation of core businesses, and (3) the strategic reallocation of resources through selective focus, and we are working to enhance corporate value.」
The medium-term management plan for fiscal 2019 through fiscal 2021, sustainable growth, selective focus, rebuilding the earnings structure, and the 3 key initiatives continue to be presented, with no material changes indicated. - FY2020-Q2RestatedAnnual report
「In the medium-term management plan for fiscal 2019 through fiscal 2021 announced on 1 April 2019, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure to respond to further changes in the business environment, we would focus on (1) concentrating on new drugs and other products by strengthening sales capabilities, (2) continued investment to build the next generation of core businesses, and (3) the strategic reallocation of resources through selective focus, and we are working to enhance corporate value.」
The medium-term management plan for fiscal 2019 through fiscal 2021, sustainable growth, selective focus, rebuilding the earnings structure, and the 3 key initiatives continue to be presented. - FY2020-Q1RestatedAnnual report
「In the medium-term management plan for fiscal 2019 through fiscal 2021 announced on 1 April 2019, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure to respond to further changes in the business environment, we would focus on (1) concentrating on new drugs and other products by strengthening sales capabilities, (2) continued investment to build the next generation of core businesses, and (3) the strategic reallocation of resources through selective focus, and we are working to enhance corporate value.」
The medium-term management plan for fiscal 2019 through fiscal 2021 and the basic policy of sustainable growth, selective focus, and rebuilding the earnings structure, together with the 3 key initiatives, have been reaffirmed. - FY2019ReframedAnnual report
「The policy of the Group's 3-year medium-term management plan (the "19-21 Medium-Term Management Plan") is to "bring together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursue selective focus for sustainable growth, and rebuild our earnings structure to respond to further changes in the business environment," and we will continue to focus on the following 3 areas so that we can respond to changes in the business environment.」
The plan was updated from the fiscal 2018–2020 plan to the fiscal 2019–2021 "19-21 Medium-Term Management Plan." The basic policy of sustainable growth, selective focus, and rebuilding the earnings structure, together with the 3 key initiatives, has been maintained. - FY2019-Q3RestatedAnnual report
「In the medium-term management plan for fiscal 2018 through fiscal 2020 announced on 2 April 2018, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure to respond to further changes in the business environment, we would focus on (1) concentrating on new drugs and other products by strengthening sales capabilities, (2) continued investment to build the next generation of core businesses, and (3) the strategic reallocation of resources through selective focus, and we are working to enhance corporate value.」
The policy and 3 key initiatives of the medium-term management plan for fiscal 2018 through fiscal 2020 continue to be presented. - FY2019-Q2RestatedAnnual report
「In the medium-term management plan for fiscal 2018 through fiscal 2020 announced on 2 April 2018, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure to respond to further changes in the business environment, we would focus on (1) concentrating on new drugs and other products by strengthening sales capabilities, (2) continued investment to build the next generation of core businesses, and (3) the strategic reallocation of resources through selective focus, and we are working to enhance corporate value.」
The medium-term management plan for fiscal 2018 through fiscal 2020, sustainable growth, selective focus, rebuilding the earnings structure, and the 3 key initiatives continue to be presented, with no material changes indicated. - FY2019-Q1RestatedAnnual report
「In the medium-term management plan for fiscal 2018 through fiscal 2020 announced on 2 April 2018, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure to respond to further changes in the business environment, we would focus on (1) concentrating on new drugs and other products by strengthening sales capabilities, (2) continued investment to build the next generation of core businesses, and (3) the strategic reallocation of resources through selective focus, and we are working to enhance corporate value.」
The medium-term management plan for fiscal 2018 through fiscal 2020 and its 3 key initiatives were reaffirmed, with no material changes to the policy indicated. - FY2018ReframedAnnual report
「The policy of the Group's 3-year medium-term management plan (the "18-20 Medium-Term Management Plan") is to "bring together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursue selective focus for sustainable growth, and rebuild our earnings structure to respond to further changes in the business environment," and we will continue to focus on the following 3 areas so that we can respond to changes in the business environment.」
The plan was updated from the fiscal 2017–2019 plan to the fiscal 2018–2020 "18-20 Medium-Term Management Plan." The basic policy of sustainable growth, selective focus, and rebuilding the earnings structure has been maintained. - FY2018-Q3RestatedAnnual report
「In the medium-term management plan for fiscal 2017 through fiscal 2019 (fiscal 2017 through fiscal 2019 in the Japanese fiscal-year system) announced on 3 April 2017, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) continued investment to build the next generation of core businesses, (2) the strategic reallocation of resources through selective focus, and (3) concentrating on new drugs and other products by strengthening sales capabilities, and we are working to enhance corporate value.」
The policy and 3 key initiatives of the medium-term management plan for fiscal 2017 through fiscal 2019 continue to be presented, with no material changes. - FY2018-Q2RestatedAnnual report
「In the medium-term management plan for fiscal 2017 through fiscal 2019 (fiscal 2017 through fiscal 2019 in the Japanese fiscal-year system) announced on 3 April 2017, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) continued investment to build the next generation of core businesses, (2) the strategic reallocation of resources through selective focus, and (3) concentrating on new drugs and other products by strengthening sales capabilities, and we are working to enhance corporate value.」
The policy and 3 key initiatives of the medium-term management plan for fiscal 2017 through fiscal 2019 continue to be presented, with no material changes indicated. - FY2018-Q1ReframedAnnual report
「In the medium-term management plan for fiscal 2017 through fiscal 2019 (fiscal 2017 through fiscal 2019 in the Japanese fiscal-year system) announced on 3 April 2017, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) continued investment to build the next generation of core businesses, (2) the strategic reallocation of resources through selective focus, and (3) concentrating on new drugs and other products by strengthening sales capabilities, and we are working to enhance corporate value.」
The plan was updated from the previous fiscal 2016–2018 plan to the fiscal 2017–2019 plan. The basic policy of sustainable growth, selective focus, and rebuilding the earnings structure, together with the 3 key initiatives, has been maintained. - FY2017-Q3RestatedAnnual report
「In the medium-term management plan for fiscal 2016 through fiscal 2018 (fiscal 2016 through fiscal 2018 in the Japanese fiscal-year system) announced on 1 April 2016, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) the strategic reallocation of resources through selective focus, (2) concentrating on new drugs and other products by strengthening sales capabilities, and (3) continued investment to build the next generation of core businesses, and we are working to enhance corporate value.」
The policy and 3 key initiatives of the medium-term management plan for fiscal 2016 through fiscal 2018 were restated, with no material changes indicated. - FY2017-Q2RestatedAnnual report
「In the medium-term management plan for fiscal 2016 through fiscal 2018 (fiscal 2016 through fiscal 2018 in the Japanese fiscal-year system) announced on 1 April 2016, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) the strategic reallocation of resources through selective focus, (2) concentrating on new drugs and other products by strengthening sales capabilities, and (3) continued investment to build the next generation of core businesses, and we are working to enhance corporate value.」
The policy and 3 key initiatives of the medium-term management plan for fiscal 2016 through fiscal 2018 were restated, with no changes indicated. - FY2017-Q1RestatedAnnual report
「In the medium-term management plan for fiscal 2016 through fiscal 2018 (fiscal 2016 through fiscal 2018 in the Japanese fiscal-year system) announced on 1 April 2016, we stated that, under the policy of bringing together the Group's comprehensive capabilities from research and development through manufacturing and sales to meet medical and healthcare needs, pursuing selective focus for sustainable growth, and rebuilding our earnings structure, we would focus on (1) the strategic reallocation of resources through selective focus, (2) concentrating on new drugs and other products by strengthening sales capabilities, and (3) continued investment to build the next generation of core businesses, and we are working to enhance corporate value.」
The policy and key initiatives of the medium-term management plan for fiscal 2016 through fiscal 2018 were restated, with no substantive changes indicated. - FY2016First statedAnnual report
「We will bring together the Group's comprehensive capabilities, from research and development through manufacturing and sales, to meet medical and healthcare needs, pursue selective focus for sustainable growth, and rebuild our earnings structure.」
Presented as the policy of the medium-term management plan for fiscal 2016 through fiscal 2018.